Welcome, Guest. Please login or register.
August 24, 2019, 11:44:43 am

Login with username, password and session length

  • Total Posts: 54312
  • Total Topics: 4602
  • Online Today: 60
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 57
Total: 57


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Keytruda Leads to Durable Response for Some People With Advanced Liver Cancer  (Read 1465 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 635
    • Hep Mag
About 16 percent of liver cancer patients who used the PD-1 checkpoint inhibitor Keytruda (pembrolizumab) after prior treatment with Nexavar (sorafenib) experienced tumor shrinkage, which in most cases lasted at least six months, according to findings presented at the 2018 Gastrointestinal Cancers Symposium (GI18) last week in San Francisco.

The median progression-free survival—meaning patients were still alive with no worsening of disease—was 4.8 months, representing an improvement over standard therapy for this difficult to treat cancer.

For more...


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.